NSEUpdates17h ago · 21 Sept 2026, 10:48 pm

Updates

Natco Pharma Limited · NATCOPHARM

✦ AI SummaryFundraise

Natco Pharma Limited has received in-principle approval from the National Stock Exchange of India Limited and BSE Limited for its Rights Issue of fully paid-up equity shares.

Analysis Scores

Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Limited has informed the Exchange regarding 'Intimation regarding receipt of In-Principle Approval for the Rights Issue '.

Attachments (1)

📄

NATCOPHARM_21092026224748_SE_Intimation_IP_Approval_21092026.pdf

pdf

Download →
View document text
September 21, 2026 To To Corporate Relationship Department The Manager – Listing BSE Ltd National Stock Exchange of India Ltd Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sirs/Madam(s), Sub: Intimation regarding receipt of In-Principle Approval for the Rights Issue We wish to inform you that the Company has received in-principle approval from National Stock Exchange of India Limited and BSE Limited on 21st September, 2026 for the Rights Issue of fully paid-up equity shares of the Company. The copies of the in-principal approval letter received from the Stock Exchange(s) are made available in the website of the Company at https://files.natcopharma.co.in/investor- relations/rights-issue-2026/ Thanking you, Yours faithfully, For Natco Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer